NPI: 1033102942 · ROANOKE, VA 24014 · General Acute Care Hospital · NPI assigned 08/25/2005
Authorized official PRESCOTT, ELEANOR controls 20+ related entities in our dataset. Read more
| Authorized Official | PRESCOTT, ELEANOR (GOVERNMENT PROGRAM MANAGER) |
| NPI Enumeration Date | 08/25/2005 |
Other providers sharing the same authorized official: PRESCOTT, ELEANOR
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 314,402 | $10.93M |
| 2019 | 458,167 | $16.83M |
| 2020 | 400,141 | $16.07M |
| 2021 | 487,294 | $18.89M |
| 2022 | 421,483 | $19.81M |
| 2023 | 455,315 | $22.67M |
| 2024 | 361,169 | $19.67M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 58,517 | 50,300 | $10.30M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 58,239 | 51,427 | $10.24M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 47,933 | 40,851 | $8.45M |
| 96361 | Intravenous infusion, hydration; each additional hour | 24,706 | 20,267 | $7.22M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3,373 | 2,866 | $4.22M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5,709 | 5,310 | $3.17M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 13,158 | 12,025 | $2.79M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 49,702 | 17,080 | $2.66M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 15,289 | 13,826 | $2.50M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 7,245 | 6,724 | $2.31M |
| 59899 | 2,669 | 2,141 | $2.27M | |
| 70450 | Computed tomography, head or brain; without contrast material | 13,576 | 12,116 | $2.24M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 18,536 | 7,343 | $2.24M |
| 64493 | 1,969 | 1,779 | $1.84M | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 5,390 | 5,063 | $1.81M |
| 77386 | 3,309 | 286 | $1.68M | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 5,872 | 4,247 | $1.59M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10,641 | 8,968 | $1.58M |
| 99220 | 28,940 | 10,092 | $1.38M | |
| 64483 | 1,826 | 1,716 | $1.37M | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 20,566 | 10,218 | $1.31M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2,016 | 1,872 | $1.28M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2,040 | 1,913 | $1.27M |
| 62323 | 2,528 | 2,407 | $1.27M | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1,612 | 1,491 | $1.26M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 16,090 | 14,703 | $1.25M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2,236 | 2,097 | $1.22M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 8,853 | 8,028 | $1.21M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 5,911 | 5,451 | $1.06M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 9,660 | 8,957 | $944K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 64,564 | 46,011 | $918K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19,394 | 16,490 | $908K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 633 | 597 | $884K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 9,586 | 7,936 | $872K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1,395 | 1,277 | $871K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 3,855 | 3,647 | $797K |
| 97161 | 6,204 | 5,861 | $796K | |
| 97162 | 6,997 | 6,374 | $709K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3,364 | 2,579 | $695K |
| 96415 | 2,278 | 1,752 | $695K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3,701 | 3,371 | $686K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4,627 | 4,240 | $671K |
| 64635 | 895 | 670 | $641K | |
| 59025 | Fetal non-stress test | 3,138 | 2,536 | $627K |
| 62321 | 1,156 | 1,096 | $613K | |
| 76830 | Ultrasound, transvaginal | 5,409 | 5,029 | $590K |
| 43235 | 1,067 | 979 | $577K | |
| 95806 | 1,078 | 1,056 | $577K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4,080 | 3,492 | $572K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 2,419 | 2,247 | $555K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 7,243 | 5,519 | $534K |
| 97802 | 5,594 | 5,100 | $504K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4,631 | 3,197 | $496K |
| 72141 | 2,522 | 2,391 | $468K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 2,001 | 1,867 | $448K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 7,972 | 7,767 | $447K |
| 74183 | 1,496 | 1,401 | $433K | |
| 76642 | 4,020 | 3,518 | $431K | |
| 70496 | 1,794 | 1,653 | $424K | |
| 95811 | 792 | 707 | $407K | |
| 71046 | Radiologic examination, chest; 2 views | 17,402 | 15,953 | $404K |
| 47563 | 115 | 106 | $400K | |
| 93971 | 3,764 | 3,423 | $389K | |
| 97803 | 4,210 | 3,729 | $387K | |
| 92523 | 2,653 | 2,582 | $366K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2,498 | 2,234 | $342K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 3,632 | 3,441 | $340K |
| 80053 | Comprehensive metabolic panel | 71,432 | 57,702 | $333K |
| 76770 | 2,255 | 2,153 | $317K | |
| 93017 | 2,741 | 2,531 | $305K | |
| 64494 | 2,016 | 1,539 | $294K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 6,198 | 3,381 | $294K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2,744 | 2,619 | $290K |
| 93308 | 1,041 | 956 | $289K | |
| 36430 | 1,636 | 1,206 | $286K | |
| 99215 | Prolong outpt/office vis | 1,215 | 1,130 | $276K |
| 77412 | 485 | 50 | $272K | |
| 74174 | 1,250 | 1,172 | $272K | |
| 74018 | 9,651 | 8,632 | $269K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 5,466 | 4,844 | $254K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 257 | 232 | $248K |
| 76536 | 2,035 | 1,923 | $242K | |
| 99234 | 11,720 | 2,685 | $241K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 366 | 350 | $237K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 63,165 | 50,141 | $237K |
| 97166 | 3,230 | 2,879 | $233K | |
| 72158 | 1,241 | 1,160 | $233K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 45,805 | 34,258 | $229K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 202 | 166 | $225K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 156 | 130 | $222K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 704 | 640 | $218K |
| 10060 | 1,771 | 1,596 | $214K | |
| 12001 | 1,065 | 998 | $212K | |
| 71250 | 3,115 | 2,897 | $212K | |
| 78431 | 253 | 238 | $211K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 5,260 | 2,360 | $211K |
| 77336 | 2,601 | 1,051 | $210K | |
| 20680 | 164 | 140 | $209K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 4,285 | 1,979 | $207K |
| 64636 | 852 | 587 | $206K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1,711 | 1,133 | $201K |
| 97165 | 1,880 | 1,747 | $201K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 3,643 | 3,375 | $189K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1,321 | 1,290 | $188K |
| 94060 | 2,961 | 2,726 | $187K | |
| 49083 | 378 | 203 | $186K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | 695 | 545 | $184K |
| 19083 | 220 | 179 | $183K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 3,080 | 2,561 | $180K |
| 20610 | 2,174 | 1,752 | $171K | |
| 76801 | 1,831 | 1,711 | $168K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 577 | 496 | $162K |
| 99235 | 7,928 | 1,827 | $160K | |
| 70491 | 958 | 910 | $158K | |
| 93970 | 1,203 | 1,108 | $155K | |
| 78492 | 204 | 179 | $152K | |
| 73221 | 735 | 687 | $152K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1,069 | 989 | $146K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 10,472 | 8,842 | $145K |
| 97116 | 4,233 | 2,386 | $144K | |
| 58661 | 57 | 39 | $144K | |
| 92526 | 2,845 | 1,718 | $144K | |
| G0378 | Hospital observation service, per hour | 4,266 | 3,507 | $142K |
| 12011 | 670 | 631 | $141K | |
| 76819 | Fetal biophysical profile; without non-stress testing | 1,412 | 967 | $137K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 78 | 77 | $136K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5,709 | 5,176 | $132K |
| 97113 | 2,326 | 1,006 | $127K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 44,733 | 37,673 | $124K |
| 93880 | 1,287 | 1,192 | $118K | |
| 93458 | 111 | 101 | $118K | |
| 70498 | 2,015 | 1,857 | $116K | |
| 76870 | 1,073 | 1,010 | $115K | |
| 73130 | 5,884 | 4,129 | $114K | |
| 97163 | 952 | 885 | $110K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 107,699 | 80,519 | $110K |
| 92610 | 1,048 | 982 | $109K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 835 | 795 | $107K |
| 73630 | 5,946 | 4,629 | $106K | |
| 77066 | Tomosynthesis, mammo | 2,556 | 2,394 | $106K |
| 72100 | 4,576 | 4,231 | $103K | |
| 77065 | Tomosynthesis, mammo | 2,662 | 2,293 | $101K |
| 71045 | Radiologic examination, chest; single view | 28,622 | 24,800 | $99K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 201 | 80 | $98K |
| 72197 | 295 | 278 | $95K | |
| 76641 | 784 | 699 | $91K | |
| 97167 | 920 | 886 | $90K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 5,535 | 5,022 | $86K |
| 44970 | 15 | 13 | $84K | |
| 71271 | 815 | 784 | $81K | |
| 94726 | 2,144 | 1,985 | $77K | |
| 73562 | 4,440 | 3,372 | $76K | |
| 12002 | 369 | 344 | $71K | |
| 72131 | 1,283 | 1,183 | $70K | |
| 70486 | 1,570 | 1,472 | $69K | |
| 94729 | 2,797 | 2,592 | $69K | |
| 73030 | 5,046 | 4,293 | $67K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | 10,190 | 8,643 | $65K |
| 80047 | 16,033 | 14,209 | $65K | |
| 83880 | 6,974 | 6,083 | $65K | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 447 | 429 | $62K |
| 70360 | 1,157 | 1,129 | $62K | |
| 58571 | 18 | 14 | $61K | |
| 87641 | 4,287 | 3,926 | $60K | |
| J3490 | Unclassified drugs | 216,135 | 79,001 | $58K |
| 77334 | 376 | 270 | $57K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | 118 | 67 | $55K |
| 97804 | 581 | 526 | $54K | |
| 84484 | 32,356 | 22,402 | $54K | |
| 90715 | 2,885 | 2,681 | $52K | |
| 73610 | 4,151 | 3,617 | $50K | |
| 76775 | 500 | 472 | $49K | |
| 77300 | 740 | 649 | $49K | |
| 76882 | 475 | 436 | $47K | |
| 73502 | 3,607 | 3,255 | $47K | |
| 93325 | 1,419 | 1,298 | $46K | |
| 72040 | 2,000 | 1,812 | $45K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 731 | 655 | $45K |
| 83036 | Hemoglobin; glycosylated (A1C) | 10,844 | 9,857 | $44K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 3,034 | 2,952 | $41K |
| 47562 | 14 | 13 | $41K | |
| 72170 | 1,988 | 1,876 | $41K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 472 | 240 | $40K |
| 85610 | 24,060 | 17,783 | $40K | |
| 77470 | 58 | 54 | $39K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2,508 | 2,365 | $39K |
| 77072 | 622 | 609 | $38K | |
| 97535 | Self-care/home management training, each 15 minutes | 1,390 | 808 | $38K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 13,826 | 9,917 | $38K |
| 96375 | Therapeutic injection; each additional sequential IV push | 34,042 | 25,655 | $37K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4,790 | 4,375 | $37K |
| 75561 | 102 | 95 | $36K | |
| 72156 | 184 | 168 | $36K | |
| 73700 | 368 | 339 | $35K | |
| 82962 | 40,226 | 20,263 | $35K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 5,024 | 4,399 | $34K |
| 36415 | Collection of venous blood by venipuncture | 38,705 | 27,492 | $33K |
| 77002 | 262 | 246 | $33K | |
| 86850 | 13,068 | 11,706 | $33K | |
| 87040 | 4,037 | 3,157 | $33K | |
| 88307 | 2,035 | 1,624 | $32K | |
| 73564 | 2,358 | 1,957 | $32K | |
| C1769 | Guide wire | 5,205 | 4,272 | $32K |
| 86923 | 1,434 | 1,020 | $31K | |
| 73110 | 2,463 | 2,144 | $30K | |
| 76604 | 960 | 898 | $28K | |
| 93922 | 364 | 353 | $28K | |
| 95819 | 145 | 132 | $28K | |
| 77338 | 70 | 62 | $27K | |
| 87510 | 3,150 | 2,895 | $27K | |
| 76937 | 548 | 483 | $27K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 89 | 86 | $27K |
| 72110 | 1,123 | 995 | $26K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 17,031 | 11,105 | $26K |
| 58558 | 14 | 12 | $24K | |
| 86900 | 13,632 | 12,210 | $24K | |
| 76885 | 176 | 167 | $24K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 79 | 75 | $23K |
| 73560 | 1,814 | 1,498 | $23K | |
| 77062 | 1,161 | 1,127 | $23K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 28 | 26 | $22K |
| 72146 | 290 | 269 | $22K | |
| 73590 | 2,333 | 1,980 | $21K | |
| 86803 | 1,961 | 1,818 | $20K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 125 | 121 | $20K |
| 85027 | 12,197 | 9,907 | $20K | |
| 83605 | 12,706 | 10,573 | $19K | |
| 72050 | 888 | 819 | $19K | |
| 94660 | 94 | 48 | $19K | |
| 76813 | 303 | 286 | $19K | |
| 97022 | 589 | 248 | $19K | |
| 88342 | 4,122 | 3,441 | $19K | |
| 77061 | 751 | 682 | $18K | |
| 95816 | 95 | 86 | $18K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1,091 | 978 | $17K |
| 27096 | 44 | 36 | $17K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 11,805 | 10,071 | $17K |
| 73140 | 943 | 863 | $17K | |
| 80076 | 3,991 | 3,394 | $16K | |
| 82565 | 6,065 | 5,379 | $16K | |
| 77295 | 12 | 12 | $16K | |
| 96376 | 17,033 | 10,759 | $16K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 49,784 | 40,220 | $15K |
| 73090 | 1,649 | 1,481 | $15K | |
| 50435 | 12 | 12 | $15K | |
| 64450 | 89 | 81 | $15K | |
| 93351 | 40 | 39 | $15K | |
| 94010 | 335 | 324 | $15K | |
| 75574 | 58 | 56 | $15K | |
| 96367 | 541 | 429 | $14K | |
| 87660 | 3,150 | 2,895 | $14K | |
| 90686 | 2,144 | 1,936 | $14K | |
| 64415 | 40 | 39 | $14K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 12,957 | 5,328 | $14K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 1,586 | 1,481 | $14K |
| 64495 | 81 | 72 | $13K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 1,982 | 1,813 | $13K |
| 81002 | 5,650 | 4,592 | $13K | |
| 94667 | 99 | 84 | $13K | |
| 86901 | 13,833 | 12,393 | $13K | |
| 85379 | 2,496 | 2,302 | $13K | |
| 73080 | 1,356 | 1,230 | $13K | |
| 88341 | 2,439 | 1,728 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 53,824 | 37,185 | $12K |
| 92611 | 222 | 205 | $12K | |
| 74230 | 106 | 99 | $12K | |
| 11721 | 1,320 | 1,040 | $12K | |
| 73552 | 1,126 | 965 | $11K | |
| 97760 | 219 | 205 | $11K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 2,803 | 2,354 | $11K |
| J2704 | Injection, propofol, 10 mg | 42,099 | 34,147 | $11K |
| 81001 | 28,582 | 25,002 | $11K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 5,051 | 4,775 | $11K |
| 77080 | 182 | 176 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4,783 | 4,366 | $10K |
| 80061 | Lipid panel | 2,665 | 2,350 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | 5,175 | 4,679 | $9K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 32,964 | 26,207 | $9K |
| 64490 | 13 | 12 | $9K | |
| 90732 | 479 | 443 | $8K | |
| 84145 | 800 | 730 | $8K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 14 | 14 | $8K |
| 85014 | 16,961 | 14,841 | $8K | |
| 83735 | 16,257 | 12,298 | $8K | |
| 31575 | 62 | 55 | $8K | |
| 99153 | Mod sedat endo service >5yrs | 2,550 | 2,244 | $8K |
| 72157 | 71 | 66 | $8K | |
| 64447 | 43 | 38 | $8K | |
| 82803 | 5,226 | 4,501 | $8K | |
| 78499 | 57 | 57 | $7K | |
| J7050 | Infusion, normal saline solution, 250 cc | 24,095 | 13,389 | $7K |
| 87632 | 405 | 385 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 866 | 778 | $7K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 152,696 | 22,937 | $7K |
| 80179 | 1,214 | 1,134 | $7K | |
| 94618 | 54 | 52 | $7K | |
| 36600 | 570 | 498 | $7K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 65 | 61 | $7K |
| 86140 | 9,741 | 8,580 | $7K | |
| 93798 | 48 | 14 | $7K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 27 | 22 | $7K |
| 72070 | 428 | 400 | $7K | |
| 74220 | 162 | 150 | $7K | |
| 84703 | 11,261 | 10,137 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 10,771 | 9,653 | $6K |
| 94727 | 202 | 191 | $6K | |
| 78320 | 26 | 25 | $6K | |
| 85730 | 7,230 | 6,454 | $6K | |
| 99152 | 3,391 | 2,963 | $6K | |
| C9399 | Unclassified drugs or biologicals | 725 | 661 | $6K |
| 94644 | 2,662 | 2,381 | $6K | |
| 81025 | 4,975 | 4,539 | $6K | |
| 87522 | Neg quan hep c or qual rna | 267 | 241 | $6K |
| 82657 | 748 | 499 | $6K | |
| 83690 | 19,986 | 16,995 | $6K | |
| 77001 | 44 | 41 | $6K | |
| 84702 | 4,254 | 3,669 | $5K | |
| 77085 | 87 | 85 | $5K | |
| 77290 | 14 | 12 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 182 | 167 | $5K |
| 73100 | 297 | 237 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 20,298 | 13,920 | $5K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 247 | 225 | $5K |
| 72082 | 93 | 92 | $5K | |
| 72128 | 138 | 132 | $4K | |
| 76942 | 106 | 98 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 18,269 | 15,180 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 30,109 | 26,836 | $4K |
| 43762 | 31 | 25 | $4K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | 37 | 36 | $4K |
| G0008 | Administration of influenza virus vaccine | 1,586 | 1,378 | $4K |
| 97035 | 137 | 50 | $4K | |
| G0379 | Direct admission of patient for hospital observation care | 12 | 12 | $4K |
| 93975 | 27 | 26 | $4K | |
| 77301 | 13 | 12 | $4K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 219 | 172 | $4K |
| 87480 | 3,140 | 2,886 | $4K | |
| 82728 | 1,429 | 1,240 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 29,895 | 24,864 | $4K |
| 74300 | 15 | 13 | $4K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 7,826 | 6,311 | $4K |
| 36416 | 8,939 | 5,107 | $4K | |
| 81003 | 10,959 | 9,757 | $3K | |
| 80143 | 1,388 | 1,281 | $3K | |
| 86920 | 302 | 242 | $3K | |
| 29125 | 96 | 93 | $3K | |
| 74022 | 507 | 468 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 1,497 | 1,372 | $3K |
| 0482T | 205 | 180 | $3K | |
| 74240 | 25 | 24 | $3K | |
| C1776 | Joint device (implantable) | 328 | 299 | $3K |
| 43760 | 13 | 12 | $3K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 46 | 41 | $3K |
| 72072 | 112 | 103 | $3K | |
| 12013 | 13 | 13 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 26,741 | 20,016 | $3K |
| 80074 | 403 | 377 | $3K | |
| 87081 | 3,821 | 3,628 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3,553 | 3,397 | $3K |
| 74019 | 221 | 214 | $3K | |
| 74178 | 14 | 12 | $3K | |
| 87116 | 214 | 172 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 16,170 | 12,335 | $3K |
| 73060 | 387 | 343 | $2K | |
| 73070 | 219 | 198 | $2K | |
| 17250 | 14 | 12 | $2K | |
| 85652 | 6,879 | 6,094 | $2K | |
| 72202 | 39 | 39 | $2K | |
| 87186 | 4,817 | 4,150 | $2K | |
| 88304 | 1,621 | 1,449 | $2K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 1,607 | 1,281 | $2K |
| 87070 | 3,525 | 2,923 | $2K | |
| C1729 | Catheter, drainage | 485 | 427 | $2K |
| 87075 | 2,894 | 2,355 | $2K | |
| A4648 | Tissue marker, implantable, any type, each | 686 | 549 | $2K |
| 74241 | 12 | 12 | $2K | |
| 87077 | 4,080 | 3,487 | $2K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 7,396 | 6,937 | $2K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 1,630 | 1,378 | $2K |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | 27 | 13 | $2K |
| J7999 | Compounded drug, not otherwise classified | 3,261 | 2,432 | $2K |
| 84100 | 4,265 | 2,939 | $2K | |
| 29515 | 12 | 12 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 7,054 | 5,853 | $2K |
| 87205 | 3,651 | 2,999 | $2K | |
| 80164 | 265 | 222 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | 2,157 | 1,987 | $2K |
| 96368 | 129 | 115 | $2K | |
| 73120 | 144 | 120 | $2K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | 26 | 24 | $2K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 960 | 875 | $1K |
| 83550 | 918 | 811 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | 324 | 195 | $1K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 1,764 | 1,191 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 11,969 | 8,900 | $1K |
| 84550 | 785 | 649 | $1K | |
| Q0247 | Injection, sotrovimab, 500 mg | 21 | 19 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 6,388 | 2,980 | $1K |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 440 | 391 | $1K |
| 93926 | 12 | 12 | $1K | |
| 97542 | 14 | 13 | $1K | |
| 51798 | 1,124 | 913 | $1K | |
| J1815 | Injection, insulin, per 5 units | 4,860 | 2,309 | $1K |
| 85045 | 841 | 748 | $1K | |
| A9585 | Injection, gadobutrol, 0.1 ml | 2,456 | 2,263 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | 8,223 | 6,464 | $1K |
| C1874 | Stent, coated/covered, with delivery system | 32 | 28 | $1K |
| J1756 | Injection, iron sucrose, 1 mg | 187 | 102 | $1K |
| 94645 | 777 | 426 | $1K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1,761 | 1,633 | $1K |
| 82550 | 2,713 | 2,265 | $1K | |
| 87015 | 2,802 | 2,033 | $955.66 | |
| 73200 | 13 | 13 | $952.97 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 248 | 157 | $935.52 |
| 93296 | 161 | 141 | $905.08 | |
| 99236 | Prolong inpt eval add15 m | 54 | 12 | $894.62 |
| 83540 | 997 | 900 | $885.11 | |
| 97014 | 27 | 13 | $881.72 | |
| 82140 | 1,347 | 1,145 | $835.89 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 2,556 | 2,011 | $831.39 |
| 93976 | 30 | 25 | $796.14 | |
| 85018 | 664 | 463 | $755.71 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,653 | 1,428 | $739.52 |
| 82607 | 891 | 807 | $739.45 | |
| 83615 | 2,047 | 1,675 | $738.89 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 7,402 | 5,535 | $736.87 |
| 82570 | 1,728 | 1,465 | $721.57 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 5,590 | 2,985 | $718.04 |
| J1644 | Injection, heparin sodium, per 1000 units | 9,193 | 3,633 | $701.28 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 510 | 482 | $678.68 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 8,583 | 6,615 | $667.57 |
| 89051 | 837 | 632 | $647.91 | |
| 90694 | 140 | 132 | $641.37 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 3,576 | 2,088 | $636.79 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 1,368 | 1,253 | $632.13 |
| 85046 | 361 | 329 | $616.69 | |
| 87088 | 1,430 | 1,298 | $594.33 | |
| J3535 | Drug administered through a metered dose inhaler | 3,144 | 2,321 | $534.83 |
| 73522 | 14 | 14 | $524.27 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 3,515 | 2,740 | $509.83 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 2,429 | 2,250 | $501.87 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 32 | 24 | $495.60 |
| A9270 | Non-covered item or service | 4,178 | 2,663 | $494.59 |
| 82330 | 357 | 265 | $492.44 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 1,871 | 1,728 | $472.19 |
| 78434 | 252 | 237 | $466.42 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 3,862 | 3,124 | $458.46 |
| 90656 | 52 | 52 | $443.41 | |
| J1790 | Injection, droperidol, up to 5 mg | 4,459 | 3,801 | $441.23 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 4,307 | 3,427 | $439.80 |
| J2060 | Injection, lorazepam, 2 mg | 3,566 | 2,638 | $397.37 |
| J3480 | Injection, potassium chloride, per 2 meq | 2,941 | 1,950 | $384.66 |
| A6198 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 48 sq. in., each dressing | 252 | 205 | $368.50 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 831 | 746 | $366.84 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 4,237 | 3,365 | $361.12 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 3,942 | 3,210 | $359.28 |
| 82746 | 546 | 495 | $356.84 | |
| 93226 | 13 | 12 | $355.85 | |
| 88313 | 211 | 181 | $338.40 | |
| 84156 | 1,053 | 890 | $327.68 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,397 | 1,144 | $321.84 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 1,535 | 1,329 | $320.91 |
| 88360 | 60 | 50 | $278.88 | |
| 90653 | 86 | 75 | $266.69 | |
| 0004A | 13 | 12 | $254.10 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 174 | 135 | $249.72 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 28 | 14 | $243.69 |
| 87340 | 664 | 580 | $241.07 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 1,296 | 611 | $237.70 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 2,232 | 1,692 | $225.02 |
| 86706 | 530 | 470 | $224.37 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 10,332 | 8,071 | $221.77 |
| S0028 | Injection, famotidine, 20 mg | 3,063 | 2,096 | $220.32 |
| 84439 | 288 | 268 | $216.31 | |
| J1940 | Injection, furosemide, up to 20 mg | 2,275 | 1,297 | $211.89 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 2,206 | 1,240 | $210.01 |
| 88112 | 27 | 24 | $206.64 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 413 | 291 | $186.05 |
| 88312 | 58 | 37 | $176.16 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 906 | 819 | $164.12 |
| 89050 | 101 | 84 | $162.61 | |
| 43450 | 45 | 40 | $151.29 | |
| L0120 | Cervical, flexible, non-adjustable, prefabricated, off-the-shelf (foam collar) | 1,080 | 907 | $145.29 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 1,347 | 1,096 | $137.09 |
| 51701 | 108 | 95 | $120.47 | |
| 90662 | 33 | 27 | $118.30 | |
| 87206 | 344 | 254 | $117.62 | |
| 86592 | 205 | 192 | $114.26 | |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 952 | 682 | $111.49 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1,647 | 1,417 | $100.57 |
| 93225 | 14 | 12 | $99.74 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 458 | 408 | $99.16 |
| J3360 | Injection, diazepam, up to 5 mg | 486 | 396 | $98.45 |
| 80069 | 44 | 28 | $97.48 | |
| G0009 | Administration of pneumococcal vaccine | 299 | 246 | $96.25 |
| 64615 | 29 | 25 | $96.24 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 763 | 546 | $94.09 |
| G0475 | Hiv antigen/antibody, combination assay, screening | 24 | 15 | $93.71 |
| 82272 | 871 | 789 | $91.47 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 1,204 | 898 | $90.18 |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | 203 | 114 | $85.53 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 368 | 293 | $83.41 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 16 | 13 | $82.68 |
| 87807 | 188 | 180 | $79.87 | |
| 87071 | 124 | 113 | $75.25 | |
| 87102 | 230 | 180 | $73.53 | |
| J3411 | Injection, thiamine hcl, 100 mg | 1,059 | 349 | $73.22 |
| 87899 | 125 | 90 | $71.21 | |
| 82150 | 141 | 127 | $70.41 | |
| 80178 | 12 | 12 | $68.72 | |
| 80050 | General health panel | 89 | 85 | $67.05 |
| 93356 | 42 | 40 | $64.49 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 2,341 | 2,074 | $64.44 |
| 82784 | 53 | 48 | $63.99 | |
| 85384 | 162 | 145 | $63.92 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 233 | 162 | $63.70 |
| 87046 | 105 | 89 | $62.59 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 29 | 13 | $60.51 |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 637 | 463 | $51.48 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 474 | 137 | $47.51 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 1,990 | 1,346 | $46.04 |
| J1630 | Injection, haloperidol, up to 5 mg | 385 | 289 | $45.63 |
| 87045 | 96 | 89 | $44.61 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 1,612 | 470 | $41.34 |
| 87449 | 88 | 70 | $40.06 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 788 | 697 | $40.02 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 1,324 | 782 | $38.26 |
| 84132 | 145 | 127 | $35.14 | |
| 87147 | 106 | 95 | $33.96 | |
| 88302 | 32 | 24 | $32.12 | |
| 82010 | 163 | 147 | $31.50 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 225 | 220 | $27.55 |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 815 | 556 | $24.47 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 123 | 90 | $19.58 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 324 | 170 | $18.81 |
| 88311 | 13 | 13 | $17.41 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 17 | 17 | $14.97 |
| 93321 | 320 | 305 | $11.81 | |
| J1836 | Injection, metronidazole, 10 mg | 562 | 324 | $8.48 |
| 94761 | 310 | 194 | $7.69 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 1,000 | 869 | $6.82 |
| 85347 | 25 | 24 | $5.67 | |
| 82945 | 29 | 26 | $5.51 | |
| C9113 | Injection, pantoprazole sodium, per vial | 62 | 30 | $5.24 |
| 86308 | 77 | 74 | $4.66 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 151 | 118 | $4.07 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 182 | 164 | $2.97 |
| 84157 | 72 | 65 | $2.85 | |
| S0030 | Injection, metronidazole, 500 mg | 1,019 | 618 | $2.27 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 623 | 425 | $0.01 |
| A4649 | Surgical supply; miscellaneous | 2,123 | 1,508 | $0.00 |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | 41 | 27 | $0.00 |
| 87324 | 32 | 28 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 57 | 39 | $0.00 |
| 51702 | 45 | 40 | $0.00 | |
| 99157 | 34 | 27 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 377 | 269 | $0.00 |
| 22853 | 28 | 26 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 118 | 99 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 540 | 380 | $0.00 |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | 671 | 465 | $0.00 |
| 20930 | 67 | 53 | $0.00 | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 68 | 62 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 132 | 122 | $0.00 |
| A9526 | Nitrogen n-13 ammonia, diagnostic, per study dose, up to 40 millicuries | 91 | 40 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 60 | 44 | $0.00 |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 23 | 13 | $0.00 |
| C1758 | Catheter, ureteral | 31 | 26 | $0.00 |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 34 | 30 | $0.00 |
| J9370 | Vincristine sulfate, 1 mg | 57 | 24 | $0.00 |
| 70250 | 13 | 12 | $0.00 | |
| J2359 | Injection, olanzapine, 0.5 mg | 34 | 27 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 158 | 125 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 209 | 137 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 160 | 113 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 175 | 120 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 158 | 74 | $0.00 |
| J2358 | Injection, olanzapine, long-acting, 1 mg | 227 | 135 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 107 | 103 | $0.00 |
| 99156 | 206 | 182 | $0.00 | |
| C1781 | Mesh (implantable) | 127 | 118 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 171 | 118 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 14 | 12 | $0.00 |
| 96409 | 85 | 51 | $0.00 | |
| J3590 | Unclassified biologics | 68 | 57 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 25 | 12 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 12 | 12 | $0.00 |
| G0269 | Placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug) | 12 | 12 | $0.00 |
| 88300 | 13 | 12 | $0.00 |